Current Report Filing (8-k)

0001563665false00015636652022-12-282022-12-28

​

​

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

​

FORM 8-K

​

CURRENT REPORT

​

Pursuant to Section 13 or 15(d) of

The Securities Exchange Act of 1934

​

Date of Report (Date of earliest event reported): December 28, 2022

​

BIOSTAGE, INC.

(Exact name of registrant as specified in its charter)

​

Delaware	001-35853	45-5210462
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

​

​

84 October Hill Road, Suite 11, Holliston, MA	01746
(Address of principal executive offices)	(Zip Code)

​

Registrant's telephone number, including area code: [phone]

​

(Former name or former address, if changed since last report)

​

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

​

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

​

Securities registered pursuant to Section 12(b) of the Act: None

​

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
N/A	N/A	N/A

​

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐

​

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

​

​

​

​

Item 8.01.Other Events.

​

On December 28, 2022, Biostage, Inc. issued a press release announcing the selection of IQVIA, a leading global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry, as the contract research organization (CRO) to manage its first clinical trial. The press release is furnished as Exhibit 99.1 and incorporated herein by reference.

 

​

​

Item 9.01.Financial Statements and Exhibits.

​

(d)Exhibits.

​

Exhibit Number		Title
99.1	​	Press Release issued by Biostage, Inc. on December 28, 2022

​

​

​

SIGNATURE

​

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

​

​	​
​		BIOSTAGE, INC.
​	​	(Registrant)
​	​
December 28, 2022	​	/s/   David Green
(Date)	​	David Green
	​	Interim Chief Executive Officer, Director and Chairman

​

​

​